✦ LIBER ✦

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

✍ Scribed by Masakazu Toi; Jeff Sperinde; Weidong Huang; Shigehira Saji; John Winslow; Xueguang Jin; Yuping Tan; Shinji Ohno; Seigo Nakamura; Hiroji Iwata; Norikazu Masuda; Kenjiro Aogi; Satoshi Morita; Christos Petropoulos; Michael Bates

Book ID: 115010235
Publisher: BioMed Central
Year: 2010
Tongue: English
Weight: 393 KB
Volume: 10
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-10-56

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical utility of serum HER2/neu in mo

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

✍ Francisco J Esteva, Carol D Cheli, Herbert Fritsche… 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 195 KB

Clinical significance of p95HER2 overexp

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

✍ Tural, D; Serdengecti, S; Demirelli, F; Öztürk, T; İlvan, S; Turna, H; Özgüroglu 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 894 KB

490 Long term survival and incidence of

490 Long term survival and incidence of brain metastasis in HER2- positive (HER2+) metastatic breast cancer patients (MBC) treated with trastuzumab (T): an institutional based review

✍ V. Diéras; M.N. Guilhaume; M. Fall; J.Y. Pierga; P. Beuzeboc; P. Cottu; C. Simon 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Clinical outcomes and treatment practice

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

✍ Olson, Erin M.; Najita, Julie S.; Sohl, Jessica; Arnaout, Amal; Burstein, Harold 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 695 KB

Role of HER3 expression and PTEN loss in

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

✍ Esteva, F.J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 318 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man